Investigators accessed longitudinal human data from ebola virus vaccination for signals of efficacy against the Bundibugyo species now surging in the Democratic Republic of Congo.
|Articles|October 23, 2019
Antibiotic-Resistant H Pylori is on the Rise in Europe
Author(s)Jonna Lorenz
Helicobacter pylori resistance to clarithromycin more than doubled during the past 20 years, according to new research presented at UEG Week Barcelona 2019.
Advertisement
Resistance to antibiotics commonly used to treat Helicobacter pylori (H pylori) infection has more than doubled in Europe during the past 20 years, according to new research.
The study, presented at UEG Week Barcelona 2019, analyzed 1232 patients from 18 countries and found increases in resistance to clarithromycin, levofloxacin, and metronidazole between 1998 and 2018.
Resistance to clarithromycin saw the sharpest increase, rising to 21.6% last year, up from 9.9% in 1998. Lead investigator Francis Megraud, MD, professor of bacteriology at University of Bordeaux, and founder and current secretary of the European Helicobacter & Microbiota Study Group, told Contagion® that the results weren’t surprising because they follow a trend.
“H pylori resistance to clarithromycin is slowly increasing during the last 20 years in Europe. It is over the threshold defined to test it before to prescribe it (15%) except in Northern countries,” Megraud told Contagion®.
The rate was highest in southern Italy at 36.9%, Croatia at 34.6%, Greece at 30%, Poland at 28.5% and Bulgaria at 26.9%. It was lowest in Denmark at 5%, Latvia at 6.8%, Norway at 8.9%, the Netherlands at 9.2% and Lithuania at 13%.
Rates of resistance to levofloxacin rose from 14.1% in 2008 to 16.3% in 2018, and for metronidazole, the resistance rates were 33.1% in 1998, 34.9% in 2008 and 39.1% in 2018.
The high rates of resistance in some countries may reflect overconsumption of antibiotics and lack of support for programs aimed at curbing resistance. Investigators will work to correlate the study data with data of antibiotic consumption in different European countries, Megraud said.
“When it is not possible to test the patient H pylori strain, it is important to have some knowledge on the global resistance in the country or area especially for clarithromycin and levofloxacin,” Megraud told Contagion®.
The increase in antibiotic resistance raises concerns that treatment options will become increasingly limited and ineffective if new therapies aren’t developed and that the incidence of associated conditions such as gastric cancer and peptic ulcer disease will remain high, Megraud said in a
Antibiotic resistance is one of the biggest threats to global health. Infections from resistant bacteria cause more than 750,000 deaths each year, a number that is expected to rise dramatically unless urgent action is taken, according to the news release.
Clarithromycin-resistant H pylori is among a list of pathogens
Antimicrobial stewardship programs worldwide aim to limit unnecessary exposure to antibiotics. One focus is to
Meanwhile, work to develop novel treatments for antimicrobial-resistant infections continues.
In July, the US Food and Drug Administration granted Priority Review designation to RedHill Biopharma Ltd.'s New Drug Application for
Advertisement
Related to this article
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Advertisement
Advertisement